Carbamazepine Treatment for Cocaine Dependence - 5

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00000191

Recruitment Status : Completed

First Posted : September 21, 1999

Last Update Posted : May 28, 2015

Sponsor:

Collaborator:

National Institute on Drug Abuse (NIDA)

Information provided by (Responsible Party):

James Cornish, University of Pennsylvania

Study Description

Brief Summary:

The purpose of this study is to assess carbamazepine as a pharmacotherapy for cocaine dependence.

Condition or disease	Intervention/treatment	Phase
Cocaine-Related Disorders	Drug: Carbamazepine	Phase 2

Study Design


Study Type :	Interventional (Clinical Trial)
Enrollment :	0 participants
Primary Purpose:	Treatment
Official Title:	Carbamazepine Treatment for Cocaine Dependence
Study Start Date :	January 1991
Actual Primary Completion Date :	February 1994
Actual Study Completion Date :	February 1994

Resource links provided by the National Library of Medicine

Drug Information available for: Cocaine hydrochloride Carbamazepine

U.S. FDA Resources

Arms and Interventions

Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	21 Years to 51 Years (Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000191

Locations


United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104 6178

Sponsors and Collaborators

University of Pennsylvania

National Institute on Drug Abuse (NIDA)

Investigators


Principal Investigator:	James Cornish, M.D.	University of Pennsylvania

More Information

Publications:

Cornish JW, Maany I, Fudala PJ, Neal S, Poole SA, Volpicelli P, O'Brien CP. Carbamazepine treatment for cocaine dependence. Drug Alcohol Depend. 1995 Jun;38(3):221-7.


Responsible Party:	James Cornish, Principal Investigator, University of Pennsylvania
ClinicalTrials.gov Identifier:	NCT00000191 History of Changes
Other Study ID Numbers:	NIDA-00144-5 3R01DA012268 ( U.S. NIH Grant/Contract ) K20-00144-5
First Posted:	September 21, 1999 Key Record Dates
Last Update Posted:	May 28, 2015
Last Verified:	May 2015

Keywords provided by James Cornish, University of Pennsylvania:


Cocaine Dependence Carbamazepine

Additional relevant MeSH terms:


Cocaine-Related Disorders Substance-Related Disorders Chemically-Induced Disorders Mental Disorders Cocaine Carbamazepine Anesthetics, Local Anesthetics Central Nervous System Depressants Physiological Effects of Drugs Sensory System Agents Peripheral Nervous System Agents Vasoconstrictor Agents Dopamine Uptake Inhibitors	Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Dopamine Agents Neurotransmitter Agents Anticonvulsants Antimanic Agents Tranquilizing Agents Psychotropic Drugs Analgesics, Non-Narcotic Analgesics Cytochrome P-450 CYP3A Inducers Cytochrome P-450 Enzyme Inducers

To Top